secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001645113-26-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure reports record FY2025 revenue $655M (+8% YoY); appoints Frank Leonard as CEO
--------------------------------------------------------------------------------

- Preliminary FY2025 net revenue $655.4M (+8% YoY); Q4 revenue $174.4M (+8% YoY).
- Cash and investments $448.3M after repaying $561M convertible notes due Nov 2025.
- Active TTFields patients reached 4,620 globally; Optune Gio prescriptions +6% in Q4.
- Frank Leonard, previously President, appointed CEO in December 2025.
- Filed PMA for TTFields in brain metastases from NSCLC; topline data expected Q1-Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000003/0001645113-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000003/nvcr-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer